HR Execs on the Move

AEG Vision

www.aegvision.com

 
AEG Vision supports and empowers eyecare professionals to grow their practices while elevating focus on delivering excellent eyecare.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.aegvision.com
  • 4835, Lyndon B Johnson Freeway
    Farmers Branch, TX USA 75244
  • Phone: 972.370.5552

Executives

Name Title Contact Details

Similar Companies

Maitri Medicinals

Maitri Medicinals cultivates, produces and dispenses quality medical marijuana products to patients in Pittsburgh and Uniontown Pennsylvania who suffer from qualifying medical conditions and diseases.

Athenex

Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.

Radioisotope Life Sciences

RLS (Radioisotope Life Sciences), the third-largest nuclear medicine pharmacy network in the United States, owns and operates 31 radiopharmacies across 18 states, offering an extensive portfolio of molecular imaging products. We endeavor to supply the highest quality radiopharmaceuticals in the industry by dispensing 100 percent of injectable unit dose products in clean rooms built to ISO 1644-1 specifications. In support of our commitment to quality, we provide tailored solutions and exceptional service to our more than 1500 customers.

NightstaRx

Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies.